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endothelial cells enriched during
chemotherapy-induced regeneration and
development. These findings give insight
into the angiocrine factors and regulatory
programs driving bone marrow recovery
after injury.
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Bone marrow formation requires an orchestrated
interplay between osteogenesis, angiogenesis, and
hematopoiesis that is thought to be mediated by
endothelial cells. The nature of the endothelial cells
and the molecular mechanisms underlying these
events remain unclear in humans. Here, we identify
a subset of endoglin-expressing endothelial cells en-
riched in human bone marrow during fetal ontogeny
andupon regenerationafter chemotherapeutic injury.
Comprehensive transcriptional characterization by
massive parallel RNA sequencing of these cells re-
veals a phenotypic andmolecular similarity tomurine
type H endothelium and activation of angiocrine fac-
tors implicated in hematopoiesis, osteogenesis, and
angiogenesis. Interleukin-33 (IL-33) was significantly
overexpressed in these endothelial cells and pro-
moted the expansion of distinct subsets of hemato-
poietic precursor cells, endothelial cells, as well as
osteogenic differentiation. The identification and
molecular characterization of these human regenera-
tion-associated endothelial cells is thus anticipated
to instruct the discovery of angiocrine factors driving
bone marrow formation and recovery after injury.
INTRODUCTION
Endothelial cells (ECs) govern tissue development and regener-
ation by signaling molecules on their cell surface and the release
of factors, such as cytokines and extracellular matrix proteins.
This angiocrine function of the endothelium drives tissue devel-
opment and regeneration in multiple organs.
In the hematopoietic system, studies in mice have revealed
pivotal contributions of ECs to the formation and regeneration
of bone and bone marrow (BM) (Hooper et al., 2009; Ramasamy
et al., 2016). Coordinated activation of osteogenesis, angiogen-
esis, and hematopoiesis is required for BM regeneration after666 Cell Reports 22, 666–678, January 16, 2018 ª 2017 The Author(s
This is an open access article under the CC BY-NC-ND license (http://tissue injury (Rafii et al., 2016; Ramasamy et al., 2015) induced
by irradiation or chemotherapy. ECs support the proper regener-
ation of the hematopoietic system after myeloablation (Butler
et al., 2010; Hooper et al., 2009; Kobayashi et al., 2010). Engraft-
ment and repopulation of hematopoietic stem and progenitor
cells (HSPCs) in mice is dependent on the regeneration of sinu-
soid ECs, which are vulnerable to toxic injury (Hooper et al.,
2009). Sinusoid regeneration is mediated through vascular
endothelial growth factor receptor 2 (VEGFR2) signaling, the
blockage of which resulted in delayed reconstitution of periph-
eral blood values in irradiated mice (Hooper et al., 2009).
ECs do not seem to be created equally in their ability to drive or
contribute to bone and hematopoietic development and regen-
eration. Recent studies in mice have identified a specialized
endothelial subset that controls the number of HSPCs in addition
to coupling angiogenesis and osteogenesis (Kusumbe et al.,
2014, 2016; Ramasamy et al., 2014). This endothelial subtype,
dubbed type H endothelium for its high expression of endomucin
and CD31, is enriched in the bone metaphysis at the endosteal
surface, where it is adjacent to osteoprogenitor cells and gives
rise to sinusoidal endothelial vessels. Importantly, insight into
the molecular programs underlying the capacity of this endothe-
lial subtype to drive angiogenesis and osteogenesis enabled its
pharmacologic manipulation in mice, resulting in increased
bone formation (Kusumbe et al., 2014; Ramasamy et al., 2015).
Taken together, various studies indicate that specified EC-
derived signals can orchestrate complex multicellular network
interactions in the mammalian marrow, driving bone formation
and regeneration under stress conditions. These findings in mu-
rine models open the perspective of EC-instructed strategies to
regenerate bone and marrow in humans, both in degenerative
conditions as well as after injury, such as chemotherapy and
irradiation. Translation of these important findings to human
regenerative medicine, however, will be critically dependent on
our ability to identify and interrogate molecularly equivalent
human ECs driving ontogeny and regeneration.
Here, we describe the identification of a human EC subtype
that is strongly associated with human fetal BM development
and regeneration after chemotherapeutic injury. This EC displays
striking immunophenotypic and molecular commonalities with).
creativecommons.org/licenses/by-nc-nd/4.0/).
type H endothelium in mice, including transcriptional activation
of programs and angiocrine factors previously related to BM
recovery in mice. Interleukin 33 (IL-33) is identified as a putative
regenerative factor facilitating hematopoietic expansion and
bone mineralization ex vivo, thus supporting the notion that the
transcriptome of this human EC may serve as an important
resource instructing discovery as well as validating the relevance
of findings in murine models to human regenerative medicine.
RESULTS
Identification of Endoglin (CD105)-Expressing ECs
Associated with BM Regeneration after
Chemotherapeutic Injury
To identify niche cells potentially implicated in the regeneration
of the hematopoietic system in humans, we interrogated the
composition of the hematopoietic niche during recovery after
chemotherapeutic injury. Chemotherapeutic exposure causes
damage to endothelial, hematopoietic, and osteolineage cells
within the BM (Hooper et al., 2009; Kopp et al., 2009; Lerner
and Harrison, 1990; Xian et al., 2006), resulting in a prolonged
neutropenia associated with considerable morbidity and mortal-
ity in humans. Flow cytometric assessment of the niche
(7AADCD45CD235a; Figure 1A) composition in the regener-
ating BM of acute myeloid leukemia (AML) patients (see Experi-
mental Procedures) revealed an unaltered frequency of ECs
(CD31+CD9+) (Barreiro et al., 2005) in comparison to marrow un-
der homeostatic conditions (healthy donors) (22.1% ± 2.24%
versus 31.57% ± 9.66%; p = 0.15 by unpaired Student’s t test)
(Figures 1A and 1B). To identify putative immuno-markers
of EC subtypes emerging during regeneration, we per-
formed massive parallel RNA sequencing (RNA-seq) of the fluo-
rescence-activated cell sorting (FACS)-purified endothelial
compartment (CD31+CD9+) (Figure 1A). A total of 903 transcripts
were found to be significantly differentially expressed in ECs in
the regenerative marrow in comparison to ECs from normal,
steady-state marrow (glmLRT function, EdgeR; false discovery
rate [FDR] < 0.05). The top 200 overexpressed transcripts con-
tained 16 genes encoding for cluster of differentiation (CD)
molecules, among which CD105 (endoglin) (Table S1), a co-re-
ceptor for transforming growth factor b (TGF-b) promoting angio-
genesis (Cheifetz et al., 1992; Duff et al., 2003) (Miller et al., 1999)
and previously associated with tissue injury (Wang et al., 1995).
CD105 protein levels, assessed by FACS analysis (Figure 1C),
identified a distinct subset of CD105-expressing ECs strongly
enriched in the regenerative marrow compared with normal
BM (10.81% ± 2.14% versus 0.48% ± 0.24% of CD31+CD9+;
p = 0.043) (Figure 1D). The presence of this endoglin-expressing
subset was temporally restricted, as it was (virtually) absent in
AML patients at diagnosis (0% ± 0%of CD31+CD9+ cells) or after
full recovery of peripheral blood values (in complete remission)
(1.27% ± 0.66% of CD31+CD9+ cells) (Figure 1E).
Endoglin-Expressing ECs Are Enriched in theMouse BM
after Chemotherapeutic Myeloablation
To confirm our observation that the CD105-expressing subset of
ECs is enriched during BM regeneration and establish a broader
relevance for mammalian biology, we next translated our obser-vations to an experimental setting in which we exposed C57BL/6
wild-type mice to a myeloablative dose of the chemotherapeutic
agent 5-fluorouracil (5FU) or PBS (vehicle control). The endoglin-
expressing subset constituted a rare subpopulation of endothe-
lial (CD31+) cells in the steady-state adult BM niche (0.05% ±
0.02% of CD45Ter119 cells) and in the collagenased bone
niche (0.42% ± 0.12% of CD45Ter119 cells) (Figures 2A, 2B,
S1A, and S1B). This fraction increased significantly after admin-
istration of 5FU in the BM (0.65% ± 0.15% of CD45Ter119
cells, fold-change (FC) increase of 13.6 ± 3.2, p = 0.026) and
collagenased bone (8.18% ± 1.43% of CD45Ter119 cells,
FC increase of 19.6 ± 3.4, p = 0.007) (Figures 2A, 2B, S1A, and
SB), confirming a relative increase of this specific subset in the
regenerative phase after myeloablation. Of note, the absolute
number of CD31+CD105+ ECs in the BM did not increase after
exposure to 5FU (Figure 2C), suggesting that selection of these
cells under chemotherapeutic pressure (rather than absolute
expansion) may be implicated.
CD105 (Endoglin)-Expressing ECs Are Enriched in the
Human BM during Fetal Development
The temporally restricted enrichment of CD105-expressing ECs
during recovery after chemotherapeutic injury suggests that this
cell type could potentially be implicated in regeneration and
hematopoietic niche formation. To corroborate this notion, we
sought to define other conditions in human biology where angio-
genesis, osteogenesis, and hematopoiesis are synergistically
activated. In human fetal bone development, hematopoiesis
shifts from the fetal liver to the bones starting at week 10 after
gestation. During this process, angiogenesis, osteogenesis,
and hematopoiesis are tightly coupled to allow coordinated
bone and hematopoietic development (Cosxkun et al., 2014;
Jagannathan-Bogdan and Zon, 2013; Medvinsky et al., 2011).
Invasion of blood vessels into the mesenchymal condensate is
crucial for the coordinated activity of chondrocytes and osteo-
blasts, and each of these cell types stands in spatial and molec-
ular interaction with ECs (Maes, 2013; Salazar et al., 2016).
Flow cytometric dissection of the endothelial composition of
fetal BM at gestational week 15–20 revealed a striking predom-
inance of CD105-expressing cells within the endothelial
compartment (62.8% ± 5.9% of CD31+CD9+ cells) (Figures 3A
and 3B). Massive parallel sequencing of these cells confirmed
overexpression of genes encoding CD markers identified in the
ECs in regenerating BM (Figure S2A), supporting the notion
that the enrichment of these transcripts in ECs in the regenera-
tive marrow is caused by overexpression in the subset of
CD105+ ECs.
The frequency of CD105-expressing ECs within the endothe-
lial compartment was even higher when examining collagenased
fetal bone fractions (average 82.65% ± 2.5% of CD31+CD9+
cells) (Figures 3A and 3B), suggesting that this endothelial sub-
population might preferentially localize to the endosteal surface
of fetal long bones. In line with this, CD105-expressing ECs were
identified, albeit at a considerably lower frequency, in collage-
nased bone fractions of human adult postnatal bone (average
25.9% ± 5.0% of CD31+CD9+ cells) (Figures 3A and 3B).
To provide anatomical context for this CD31+CD105+ EC
subset, we performed in situ immunohistochemistry andCell Reports 22, 666–678, January 16, 2018 667
Figure 1. Identification of CD105 (Endoglin)-Expressing ECs Associated with BM Regeneration after Chemotherapeutic Injury
BM obtained by aspirates on recovery after chemotherapeutic injury (AML D17) was compared with normal adult BM.
(A) Gating strategy for identification and isolation of ECs. After doublet exclusion, 7AADmononuclear cells (MNCs) were gated based on low/negative CD45 and
CD235a expression to identify niche cells. ECs were identified as CD31+CD9+ cells within the niche.
(B) Frequency of ECs within the niche in adult steady-state (n = 9) and regenerative (n = 48) BM.
(C) Representative FACS plots revealing the existence of a CD105-expressing endothelial subset in regeneration.
(D) The frequency of CD105+ cells in the endothelial niche in normal BM (n = 9) and during regeneration after chemotherapy (n = 48).
(E) The frequency of CD105+ cells in the endothelial niche in BM aspirates of AML patients at diagnosis (n = 4) and after recovery in complete remission (n = 3).
Data represent mean ± SEM. *p < 0.05, 2-tailed unpaired Student’s t test. AML, acute myeloid leukemia; CR, complete remission; D17, day 17.
668 Cell Reports 22, 666–678, January 16, 2018
Figure 2. CD105-Expressing ECs Are En-
riched in Mice during Regeneration after
Chemotherapeutic Injury
(A) Representative FACS plots for identification of
murine BM ECs. After doublet exclusion, 7AAD
mononuclear cells (MNCs) were gated based on
low/negative CD45/ Ter119 expression to select
for BM niche cells. BM ECs were identified by
CD31 and CD105 expression.
(B) Frequency of CD105+ ECs within the murine
BM niche during S.S (n = 3 mice) and on recovery
after 5-FU (n = 5 mice).
(C) Numbers of CD105+ BM ECs during S.S (n = 3)
and after 5-FU treatment (n = 5).
(D and E) CD105+ BM ECs differentially express
IL-33 on injury. (D) Representative FACS plots. (E)
IL-33 expression in CD105+ BM ECs and CD105
BM ECs in S.S (n = 3) and after 5-FU treatment
(n = 5).
Data represent mean ± SEM. *p < 0.05, 2-tailed
unpaired Student’s t test. 5-FU = 5-fluorouracil;
S.S = steady-state.immunofluorescence on fetal femurs and core hip bone biopsies
obtained from adults. CD31+CD105+ ECs were observed in the
trabecular bone area of the metaphysis of fetal femurs (Figures
3C, S3A, and S3B) at a significantly higher frequency than in
the trabecular bone of adult BM. The majority of vascular struc-
tures in both fetal and adult human bone were lined with
CD31CD105+ ECs, previously shown to be sinusoid ECs.
CD31+CD105 cells were present sporadically in adult bone.
Collectively, these findings identify a human endothelial
subtype that is enriched in collagenased bone fractions, preva-
lent during human fetal bone development, declines in frequency
on aging, and emerges, in a temporally restricted fashion, in the
BM during regeneration after chemotherapeutic injury. Hence-
forward, we will refer to this EC type as ‘‘human regeneration-
associated ECs’’ (hRECs).
hRECs Share Immunophenotypic and Molecular
Similarities with Murine Type H Endothelium and
Express Key Regulators of Angiogenesis and
Osteogenesis
Interestingly, similarities exist between hRECs and the recently
described specialized endothelium coordinating osteo- and
angiogenesis in mice, termed type H endothelium (Kusumbe
et al., 2014, 2016; Ramasamy et al., 2014). These include enrich-
ment at the bone surface, reduced frequencies on aging, and an
increase in frequency on genotoxic stress, suggesting that
hRECsmay reflect human equivalents of mouse type H endothe-
lium. To further investigate this, differentially expressed
transcripts in CD31+CD9+CD105+ hRECs isolated from
human fetal bone (in comparison to steady-state postnatal
CD31+CD9+CD105 cells) were related to genes reported toCell Rbe overexpressed in type H endothelium.
This confirmed elevated expression of
many transcripts previously reported to
be enriched in type H endothelium,
including genes encoding the signaturemarkers CD31 (PECAM1) and mucin-like sialoglycoprotein en-
domucin (EMCN) (Figure 4A) and vessel guidance molecules
(Ramasamy et al., 2014) (Figure 4B). Most of these genes were
similarly enriched in the CD31+CD9+ fraction of regenerative
BM (Figures 4A and 4B) (the limited number of CD105+ cells
precluded RNA-seq of this specific subset). In total, 3,718 genes
were differentially expressed (glmLRT function, EdgeR;
FDR < 0.05) in fetal bone hRECs in comparison to steady-state
postnatal BM ECs. Among the overexpressed genes were
HSPC niche factors (Figure 4C) and known angiocrine anabolic
regulators of osteogenesis and angiogenesis (Figure 4D), further
suggesting that hRECsmight be involved in hematopoietic niche
formation.
Next, transcriptional programs and signatures were interro-
gated in hRECs using gene set enrichment analysis (GSEA)
(Subramanian et al., 2005). Activated Notch signaling and stabi-
lization of HIF1a have been identified in type H endothelium as
key promotors of the formation of type H capillaries and
the release of osteogenic factors that enhance osteogenesis
(Kusumbe et al., 2014; Ramasamy et al., 2014). In line with
this, key NOTCH regulators, such as Jagged-1, DLL4, NOTCH1,
and NOTCH4 (receptors of DLL4), were upregulated in fetal
hRECs (Figure 4E), reflected in the activation of downstream
transcriptional NOTCH signaling, as demonstrated by GSEA
(Figure 4F). Similarly, gene sets related to the HIF1a pathway
were enriched in fetal hRECs according to GSEA (Figure S2B).
Other relevant molecular signatures that were identified to be
significantly enriched in hRECs include ‘‘angiogenesis’’ and
‘‘stemness’’ signatures, among which VEGF and WNT signaling
(Figure S2C). Together, the data indicate that hRECs share
immunophenotypic and molecular commonalities with murineeports 22, 666–678, January 16, 2018 669
Figure 3. CD105-Expressing ECs Are En-
riched in Fetal Development and Collagen-
ized Bone Fractions
(A) Representative FACS plots identifying CD105-
expressing ECs in fetal BM, fetal bone, and adult
bone.
(B) Frequency of CD105+ cells in the endothelial
compartment in healthy adult BM aspirates (n = 9),
fetal BM (n = 15), fetal bone (n = 21), and adult bone
(n = 9). Data represent mean ± SEM. **p < 0.01,
***p < 0.001, 1-way ANOVA (p < 0.0001) followed
by Bonferroni’s multiple comparison test.
(C) In situ immunofluorescence demonstrating
the existence of capillary structures in the trabec-
ular area of fetal long bone comprised of
CD31+CD105+ ECs (arrowheads). Sinusoid struc-
tures are CD31loCD105+. In human adult BM, the
majority of CD31+ ECs lacks CD105 expression
(asterisks). The area within the dotted line in the
adult BM represent bone tissue. Magnification,
203. White scale bar represents 100 mm.type H ECs and have a transcriptional wiring that may be
congruent with the view that these cells are implicated in the
coupling of hematopoiesis, osteogenesis, and angiogenesis in
regeneration.
IL-33 Is Expressed by hRECs and Promotes
Angiogenesis, Osteogenesis, and the Expansion of
Hematopoietic Precursor Cells
We thus hypothesized that elucidation of the transcriptome of
ECs related to hematopoietic niche formation might instruct
the discovery of pathways or proteins facilitating niche forma-
tion. In particular, angiocrine factors may be identified that
facilitate angiogenesis, osteogenesis, and hematopoiesis. To
provide proof of principle for this assumption, we focused our
attention on genes encoding secreted factors that were signif-
icantly enriched in both fetal hRECs and regenerative BM
ECs. In total, 237 genes were significantly enriched, of which
34 are genes encoding known secreted factors with a strong
correlation in levels of expression (Figure 5A). Of interest, the670 Cell Reports 22, 666–678, January 16, 2018canonical receptors of many of these
secreted proteins were overexpressed
in fetal hRECs, (MMRN2-CLEC14A,
BMP4-BMPR2, EFNA1-EPHA2/EPHA4/
EPHA7, EDN1-EDNRB, SEMA3A-NRP1/
NRP2/PLXNA2, and ADM-RAMP2/
CALCRL) (Figure S2D), suggesting the
possibility of autocrine signaling.
In addition to secreted factors with a
known role in regulating HSPC behavior,
such as plasminogen activator (PLAT)
(Ibrahim et al., 2014) and tissue factor
pathway inhibitor (TFPI) (Khurana et al.,
2013), we found significant overexpres-
sion of IL33 in hRECs (Figure 5A).
IL-33 is a pro-inflammatory cytokine
and a chromatin-associated nuclear
factor (Carriere et al., 2007). IL-33 proteinexpression in fetal hRECs was confirmed using fluorescence
microscopy (Figure 5B), and IL-33 was differentially overex-
pressed in murine CD31+CD105+ ECs in comparison to their
CD105 counterparts during regeneration (Figures 2D and 2E).
The inability to propagate sorted hRECs ex vivo (data not shown)
precluded the possibility to perform co-culture blocking experi-
ments to assess the contribution of hREC-derived IL-33 to
angiogenesis, hematopoiesis, and osteogenesis. As an alterna-
tive strategy, we exposed relevant cell types to recombinant
human IL-33 (rhIL-33).
Hematopoiesis
To test if IL-33 facilitates human hematopoiesis in vitro,
we exposed cord blood (CB) CD34+ HSPCs to rhIL-33 or vehicle
control for one week in serum-free medium containing stem
cell factor (SCF). rhIL-33 expanded the total number of
hematopoietic cells (total mononuclear cells [MNCs]) (3.4-fold
increase ± 0.29; p < 0.01) with a concomitant expansion of he-
matopoietic progenitor cells (HPCs), specifically immunopheno-
typic multipotent progenitors (MPPs) (2.5-fold increase ± 0.43;
Figure 4. hRECs Express Transcriptional
Programs Defining Niche-Forming ECs in
Mice
TranscriptomesofhRECS isolated fromhuman fetal
bone (CD45CD235CD31+CD9+CD105+) (n = 3)
and regenerative BM (CD45CD235CD31+CD9+)
(n = 3) were compared with postnatal steady-state
BM ECs (CD45CD235CD31+CD9+) (n = 7).
(A and B) Expression of genes encoding arterial
and venous markers (A), and vessel guidance
molecules previously reported to be overex-
pressed in murine type H ECs (B) (Itkin et al., 2016;
Kusumbe et al., 2014, 2016; Ramasamy et al.,
2014). Note, Sca-1 has no known human homolog
(Holmes and Stanford, 2007).
(C) Expression of established hematopoiesis-
supporting cytokines (Broudy, 1997; Sugiyama
et al., 2006; Zhang et al., 2006).
(D) Expression of genes encoding anabolic regu-
lators of angiogenesis and osteogenesis (Blu-
menfeld et al., 2002; Clines et al., 2007; Edwards
and Mundy, 2008; Oshima et al., 2002; Salani
et al., 2000; Salvucci and Tosato, 2012; Serini
et al., 2003; Shao et al., 2004; Shigematsu et al.,
1999; Tamagnone and Giordano, 2006).
(E and F) Expression of genes encoding critical
NOTCH pathway components (E) and activation of
Notch- signaling (F) as demonstrated by gene set
enrichment analysis (GSEA).
*FDR < 0.05. FDR, false discovery rate; FPKM,
fragments per kilobase million; NES, normalized
enrichment score.p < 0.05) and multilymphoid progenitors (MLPs) (2.7-fold in-
crease ± 0.15; p < 0.01) (Figures 5C and S4). Immunophenotypic
HSC numbers were not affected by exposure to IL-33. Expan-
sion of myeloid progenitor cells was confirmed in colony-forming
unit cell assays (CFU-C assays, demonstrating an increase in
granulocyte-macrophage colony-forming units (CFU-GMs)
(2.27-fold increase ± 0.21; p < 0.05) (Figure 5D).
Osteogenesis
Next, we interrogated a potential role of IL-33 in bone formation.
In human fetal bone development (endochondral ossification),
vascular invasion of chondrocytes coincides with expansion of
osteoblasts and mineralization of the matrix (Charbord et al.,
1996; Ramasamy et al., 2016). To test the role of IL-33 in this pro-
cess, the effect of rhIL-33 on the osteogenic differentiation of
human BM-derived stromal cells (BMDSCs) was assessed.
The addition of rhIL-33 to osteogenic induction medium acceler-
ated terminal differentiation of BMDSCs toward matrix-depos-
iting osteoblasts, as suggested by Alizarin red-staining (Fig-
ure 6A), indicating increased calcific matrix deposition. To
confirm this finding, we performed colorimetric assessment ofCell Rcalcium deposition, demonstrating a
striking 3.61-fold ± 0.63 (p < 0.02) in-
crease in calcium deposition of IL-33-
exposed BMDSCs in comparison to
BMDSCs cultured in osteogenic induc-
tion medium alone (Figure 6B). The prolif-
eration of BMDSCs was not affected byrhIL-33 (Figures S5A and S5B), suggesting that IL-33 exerted
its osteogenic effect by promoting osteoblastic differentiation
or the secretion of matrix proteins by osteoblasts rather than
by expanding primitive mesenchymal cells.
Angiogenesis
In line with earlier reports (Choi et al., 2009), we confirmed that
IL-33 is an angiogenic factor. shRNA-mediated knockdown of
IL-33 (Figures S5C andS5D) from human umbilical vein ECs (HU-
VECs) dramatically impaired their expansion in culture (Fig-
ure 6C), indicating that IL-33 promotes angiogenesis in an auto-
crine fashion.
IL-33 Promotes Expansion of Hematopoietic Precursor
Cells andAlters theArchitecture of theBMNiche inMice
We next studied the in vivo relevance of these effects of IL-33 on
distinct cellular components of human BM. The administration of
recombinant murine IL-33 (rmIL-33) compared with PBS control
resulted in expansion of immature (Lin) (Figure S6A) and primi-
tive progenitor (Lin, c-KIT+, Sca-1+ [LKS]) hematopoietic cells,
in particular the HPC-1 population (Figures 7A and 7B), earliereports 22, 666–678, January 16, 2018 671
Figure 5. Identification of IL-33 As a
Hematopoietic Niche Factor
(A) Transcript expression of 34 genes encoding
secreted factors significantly enriched (FDR <
0.05) in fetal bone and regenerating BM ECs (Log2
fold change in comparison to steady-state BM).
FDR: false discovery rate. FC: Fold Change.
(B) Cropped pictures (magnification, 633) of
immunostained fetal hRECs demonstrating pro-
tein expression of IL-33. White scale bar repre-
sents 20 mm.
(C and D) IL-33-mediated expansion of cord-
blood-derived myeloid and lymphoid progenitor
cells as demonstrated by (C) flow cytometric cell
counting (n = 4 independent experiments) and (D)
CFU-C confirming an increase in CFU-GMs
(n = 3 independent experiments). Data represent
mean ± SEM. *p < 0.05, 2-tailed unpaired
Student’s t test. HSC, hematopoietic stem
cell, CD90+CD45RA ; MLP, multilymphoid pro-
genitor, CD90CD45RA+; MPP, multipotent pro-
genitor, CD90CD45RA.shown to contain restricted hematopoietic precursor cells with
myeloid and lymphoid lineage potential (Oguro et al., 2013).
Expansion of a myeloid progenitor population was confirmed
with CFU-C assays (Figure S6B). Total BM cellularity and
LinKit+Sca1 cell counts remained unchanged (Figure S6C).
In addition, the number of granulocyte-macrophage progenitors
(GMPs) and myeloid cells increased after IL-33 administration
(Figures 7A, 7B, S6D, and S6E), recapitulating the expansion of
human hematopoietic myeloid precursors in vitro. Congruent
with our findings in human hematopoietic cells, immunopheno-
typic HSCs were not numerically affected by IL-33 (Figures 7A
and 7B). Interestingly, IL-33 also significantly expanded the pop-
ulation of LinKitSca1+ BM cells, previously shown to contain
early lymphoid-committed precursors with T cell, B cell, and nat-
ural killer (NK) cell potential (Kumar et al., 2008) and innate
lymphoid cells (Brickshawana et al., 2011). Hematopoietic
changes were accompanied by a relative increase, albeit not
reaching statistical significance, in CD31+CD105+ ECs as well
as LinTer119CD51+Sca cells (earlier shown to contain line-
age-committed/osteoblastic cells) (Schepers et al., 2012) within
the niche compartment (Figures S7A and S7B).
Collectively, the in vitro and in vivo data indicate that IL-33
modulates distinct cellular components of hematopoietic tissue
and has the potential to facilitate angiogenesis, hematopoiesis,
and osteogenesis, supporting the view that elucidation of the
transcriptome of hRECs may instruct the identification of modu-
lators of these processes.
DISCUSSION
Injury to the hematopoietic system, caused by chemotherapy or
irradiation, is a significant cause of morbidity and mortality in the
treatment of malignant hematopoietic disease. Studies in mice
have demonstrated a pivotal role of specific BM niche cells672 Cell Reports 22, 666–678, January 16, 2018and secreted molecules in hematopoietic recovery. Translation
of these findings to the clinic, however, is hampered, principally
by insufficient understanding of the niche cells and molecular
programs governing niche formation and hematopoietic recov-
ery in humans. Here, by cellular dissection of the BM niche in
humans during fetal development and regeneration after chemo-
therapeutic injury, we reveal the existence of a specific EC type
(hRECs) associated with these conditions. hRECs share pheno-
typic and molecular similarities with specialized ECs driving
hematopoietic niche formation in mice, expressing critical regu-
lators of hematopoiesis, osteogenesis, and angiogenesis. The
data comprise, to our knowledge, the first comprehensive
molecular characterization of human ECs on tissue regeneration
after injury.
We identified the TGF-b1 receptor endoglin (CD105) as a
marker of endothelium associated with BM (re)generation in
fetal development and after chemotherapeutic injury. Endo-
glin-expressing ECs have earlier been associated with angio-
genesis in tumors and inflammation (Kumar et al., 1996), and
loss of endoglin results in defective angiogenesis in mice (Li
et al., 1999), supporting the view that it mediates signals
governing blood vessel formation. The data indicate that
endoglin with concomitant CD31 expression marks a specific
subset of angiogenic ECs, which is further supported by obser-
vations that endoglin expression is strongly elevated in ECs of
small, capillary-like vessels at tumor edges (Miller et al., 1999;
Yoshitomi et al., 2008). Endoglin thus likely identifies a subset
of endothelium during ontogeny and regeneration that marks
an angiogenic subset, in line with observations in different
settings.
This subset revealed remarkable molecular congruence with
EC subsets identified in murine studies driving bone and BM
regeneration after injury. ECs in mice support the regeneration
of the hematopoietic system after injury, such as myeloablation
Figure 6. IL-33 Promotes Osteogenesis and
Angiogenesis In Vitro
(A and B) IL-33 accelerates terminal differentiation
of mesenchymal cells toward matrix-depositing
osteoblasts as demonstrated by (A) Alizarin red-
staining and (B) colorimetric assessment of cal-
cium deposition (n = 3 independent experiments).
(C) Knockdown of IL-33 inhibits expansion of
HUVECs. Quantification of the total number of
HUVECs over time (combined data of n = 3 inde-
pendent experiments).
Data represent mean ± SEM. *p < 0.05, 2-tailed
unpaired Student’s t test.(Butler et al., 2010; Hooper et al., 2009; Kobayashi et al., 2010),
and in recent years, several markers of specified endothelial sub-
sets exerting this function as well as the underlying mechanisms
have been revealed. Interestingly, hRECs share many character-
istics with the ECs described in these studies, including expres-
sion of the cell surface proteins Tie2/TEK (Figure S2E) (Doan
et al., 2013; Kopp et al., 2005), EMCN (Kusumbe et al., 2014;
Ramasamy et al., 2014), and Jagged1 and activation of specific
signaling pathways, including NOTCH (Butler et al., 2010; Poulos
et al., 2013). Also, hRECs express many molecules previously
shown to regulate HSPC behavior in mice, such as PLAT (Ibra-
him et al., 2014), TFPI (Khurana et al., 2013), E-selectin (ESELE)
(Figure S2E) (Winkler et al., 2012), thrombomodulin (TMBD) (Fig-
ure S2E) (Gur-Cohen et al., 2015), and tenascin C (TNC) (Fig-
ure S2E) (Nakamura-Ishizu et al., 2012).
In particular, hRECs displayed striking commonalities with
type H endothelium, a murine EC subtype that has recently
been functionally implicated in EC-driven formation of the niche
through activation of NOTCH andHIF1 signaling (Kusumbe et al.,
2014; Ramasamy et al., 2014). Commonalities with the now iden-
tified hRECs include enrichment at the bone surface, reduction in
frequency on aging, resistance to stress conditions, expression
of markers typical for both arterial (Ephn2b, Nestin, Nrp1,
Sox17, and VEGFR2), and sinusoidal vessels (VEGFR3 and
EMCN), and activation of the NOTCH and HIF1 pathways driving
regeneration.Cell RExpression of CD105 was not ad-
dressed in the studies on type H endothe-
lium, but our data in mice show that a rare
population of endoglin-expressing ECs
increases in frequency in the regenerative
phase after chemotherapy, likely reflect-
ing increased resistance to myeloablative
stress. It is noteworthy that CD105+ ECs
associated with elevated HIF-1a expres-
sion have been described in the BM of
mice on regeneration after 5-flourouracil
(5-FU) treatment (Nombela-Arrieta et al.,
2013), making it tempting to hypothesize
that these represent similar or overlap-
ping cell types.
Taken together, these immunopheno-
typic and molecular similarities between
hRECs and murine endothelial subtypesimplicated in hematopoietic niche formation point toward evolu-
tionary conservation of these cells betweenmammalian species.
They thus provide human relevance to findings inmurine studies,
supporting the notion that ECs are implicated in niche regenera-
tion in humans.
Providing experimental support for this view is challenging due
to limitations inherent to the study of human cells as well as the
inability to propagate highly purified hRECs ex vivo, precluding
co-culture studies. As an alternative approach, we exploited
elucidation of their transcriptome to identify candidate factors
driving EC-driven formation of the hematopoietic niche and
regeneration of HSPCs. We identified IL-33, a cytokine typically
associated with innate immunity and inflammation (Cayrol and
Girard, 2014), as a candidate factor. IL-33 was overexpressed
in human hRECs, and expression was increased in murine
CD31+CD105+ ECs on exposure to 5FU. Hematopoietic niche
regenerating properties of IL-33 were demonstrated by its
ex vivo capacity to facilitate hematopoiesis (increased numbers
of HPCs), osteogenesis (accelerating terminal differentiation of
BMDSCs toward matrix-depositing osteoblasts), and angiogen-
esis (expansion of HUVECs). The data follow recent reports
demonstrating IL-33 to predominantly act as an ‘‘alarmin’’
released by cells undergoing necrosis after tissue damage or
active secretion (Kakkar et al., 2012; Lee et al., 2015) and playing
anabolic roles in angiogenesis (Choi et al., 2009; Shan et al.,
2016) and osteogenesis (Saleh et al., 2011). Our finding thateports 22, 666–678, January 16, 2018 673
Figure 7. Recombinant IL-33 Expands Hematopoietic Progenitors In Vivo
(A) Representative FACS plots of PBS versus IL-33-treatedmice depicting the distribution of hematopoietic (progenitor) populations. CMP, LK, CD16/32, CD34+
cells, commonmyeloid progenitor; GMP, LK, CD16/32+, CD34+ cells, granulocyte-macrophage progenitor; HSC, LKS, CD48CD150+ cells, hematopoietic stem
cell; HPC-1, LKS, CD48+, CD150 cells, hematopoietic progenitor-1; HPC-2, LKS, CD48+, CD150+ cells, hematopoietic progenitor-2; Lin, Lineage-negative
cells; LK, Lin, c-KIT+, Sca-1 cells; LKS, Lin, c-KIT+, Sca-1+ cells; LS, Lin, c-KIT, Sca-1+ cells. MEP, LK, CD16/32, CD34 cells, megakaryocyte-erythroid
progenitor; MPP, LKS, CD48CD150 cells, multipotent progenitor.
(B) Total BM counts of GMP, LKS, HPC-1, HSC, and LS populations in PBS-treated (n = 10) and IL-33-treated (n = 5) mice. Data represent mean ± SEM. *p < 0.05,
**p < 0.01, 2-tailed unpaired Student’s t test.rhIL-33 increased the numbers of HPCs ex vivo seems congruent
with recent observations in mice, where administration of IL-33
promoted myelopoiesis (Kim et al., 2014). Of considerable inter-
est, rhIL-33 in our experiments expanded both immunopheno-
typic MLPs and MPPs, in line with observations in experiments
in mice where expansion of splenic lymphoid progenitors after
IL-33 administration resulted in enhanced defense against
opportunistic infection (Kim et al., 2014). Formal demonstration
that secretion by a defined subset of ECs is required for the
regenerative actions of IL-33 will have to await in vivo targeted
deletion experiments, because it is currently challenging to
maintain this particular subset of ECs ex vivo to enable co-cul-
ture experiments. The profound effect of IL-33 knockdown on
HUVEC proliferation and maintenance precluded the use of
this ex vivo system to address this question.
The combined findings point to a unique role of IL-33 in
mammalian species in facilitating the reconstitution of both he-
matopoietic lineages, which may be of considerable importance674 Cell Reports 22, 666–678, January 16, 2018to prepare the hematopoietic system for the extra-uterine envi-
ronment in ontogeny, but also for immune reconstitution after
injury (e.g., hematopoietic stem cell transplantation character-
ized by long-term lymphocyte depletion and ensuing opportu-
nistic infections).
The exact molecular mechanisms by which IL-33 exerts these
effects (either direct or indirect) remain to be fully elucidated.
IL-33 expression in HUVECs has been associated with a quies-
cent cellular state (K€uchler et al., 2008), and although we did
not examine the cell cycle status of CD31+CD105+, IL-33high
hRECs, this might help explain the notion that they may be rela-
tively resistant to chemotherapeutic myeloablation. We can
speculate that quiescent CD31+CD105+, IL-33high hRECs
survive chemotherapy and are ‘‘activated’’ to release IL-33 as
an anabolic hematopoietic factor. In this context, it is noteworthy
that hRECs display transcriptional activation of DLL4 and the
Notch pathway, earlier shown to be an important driver of
IL-33 expression (Sundlisaeter et al., 2012).
Regardless of the underlying molecular mechanisms of IL-33
expression, the data support the notion that elucidation of the
transcriptome of hRECs may instruct the identification of the
proteins and pathways driving niche formation after injury. It is
conceivable that receptor-ligand interactions allow targeting of
these cells to drive regeneration (as previously shown by phar-
macologic modulation of NOTCH signaling in mice [Ramasamy
et al., 2014]). In this context, it is noteworthy that transcriptional
profiling of fetal hRECs revealed overexpression of genes en-
coding secreted factors as well as their receptors, suggesting
the potential relevance of autocrine signaling in the biology of
hRECs. Alternatively, it would be worthwhile to test the ability
of identified secreted factors to expand human HSPCs ex vivo,
either directly or in co-culture settings with mesenchymal
elements.
Collectively, the identification of human ECs associated with
hematopoietic niche formation and the elucidation of their tran-
scriptome are anticipated to provide a valuable resource for
the regenerative community to relate findings in animal models
to human biology and to instruct in vivo and ex vivo approaches
to foster EC-driven regeneration of the hematopoietic system
after injury.
EXPERIMENTAL PROCEDURES
Human BM Samples
BM aspirates of AML patients were collected at diagnosis, 17 days after the
start of chemotherapy (3+7 schedule of chemotherapy with anthracycline
and cytarabin), and on achievement of complete remission (median age: 65
years, range: 28–76 years). The time point of 17 days after the start of chemo-
therapy represents the neutropenic phase, 10 days after administration of
chemotherapy and, on average, 4 days before recovery of neutropenia. Con-
trol marrow was obtained by aspiration from donors for allogeneic transplan-
tation (median age: 40 years, range: 39–48 years) after obtaining written
informed consent. In addition, trabecular hip bone samples were collected
from patients undergoing hip replacement surgery (median age: 55 years,
range: 22–71 years). Human fetal long bones (median age: 18 gestational
weeks, range: 15–20 gestational weeks) were obtained from elective abor-
tions. Gestational age was confirmed by ultrasonic measurement of skull
diameter and femoral length. The use of human samples with informed con-
sent was approved by the Institutional Review Board of the Erasmus Medical
Center (the Netherlands) in accordance with the Declaration of Helsinki.
RNA-seq and GSEA Analysis
RNA of sorted cells was extracted according to the manufacturer’s instruc-
tions for RNA isolation with GenElute LPA (Sigma). cDNA was prepared using
the SMARTer procedure (SMARTer Ultra Low RNA Kit, Clonetech). Library
preparation and RNA-seq was performed as previously described and vali-
dated for low input (Chen et al., 2016). Finally, GSEA was performed on the
fragments per kilobase million (FPKM) values using the curated C2 collection
of gene sets within the Molecular Signatures Database (MSigDB) (Subrama-
nian et al., 2005).
Mice and In Vivo Procedures
C57BL/6JOlaHsd wild-type mice were purchased from Envigo. Animals were
maintained in specific pathogen-free conditions in the Experimental Animal
Center of Erasmus MC (EDC). To study the murine niche in regenerative con-
ditions, adult mice (7–12 weeks old) were intraperitoneally administered
250 mg/kg 5-FU and then sacrificed 7 days after 5-FU treatment. To study
the effect of rmIL-33 on steady-state hematopoiesis and the BM niche, adult
mice (7–14 weeks old) were intraperitoneally injected with 2 mg of recombinant
IL-33 (catalog no. 580504, BioLegend) or PBS vehicle control daily for 6
consecutive days and then sacrificed.All mice were sacrificed by cervical dislocation. Mouse BM and bone frac-
tion cells were isolated as previously described (Zambetti et al., 2016). Periph-
eral blood was collected from the submandibular vein in K2EDTA-coated
microtainers (BD) and analyzed using a Vet ABC counter (Scil Animal Care).
Animal studies were approved by the Animal Welfare/Ethics Committee of
the EDC in accordance with legislation in the Netherlands (approval no.
EMC 4015).
Liquid Culture of CD34+ CB Cells
A total of 20,000 CD34+ CB cells in 200 mL per well were cultured in
StemSpan SFEM (Stem Cell Technologies, catalog no. 9600) with SCF
(50 ng/mL, Cellgenix, Freiburg, Germany), in a flat-bottom, 96-well plate
at 37C and 5% CO2. Two mL mQ solution containing only rhIL-33 protein
(ProSpec, catalog number CYT-425) or just mQ (vehicle control) was added
to the medium for a final concentration of 25 ng/mL rhIL-33 or 1% mQ,
respectively. The medium was refreshed every 3 or 4 days, and cells
were collected at day 7 for FACS analysis or for hematopoietic colony
forming-unit assay.
Culture of Human BMDSCs
Human BMDSCs (catalog no. PT-2501, Lonza) were cultured as described
previously (Brum et al., 2015). For osteogenic differentiation, BMDSCs were
cultured in osteogenic induction medium (aMEM medium containing 10%
heat-inactivated fetal calf serum [FCS] supplemented with 100 nM dexameth-
asone and 10mM b-glycerophosphate) with rhIL-33 (250 ng/mL) or mQ vehicle
control for 3 weeks. Medium was refreshed every 3–4 days.
Culture and shRNA-Mediated Knockdown of IL-33 in HUVECs
HUVECs were expanded in EGM-2 Bulletkit medium (CC-3156 and CC-4176,
Lonza). RNAi was achieved by lentiviral transduction. Briefly, shRNAs against
IL-33 (sh19: TRCN0000135845 and sh20: TRCN0000135846) and a non-target
control (shControl: SHC002 [SHC]) cloned in the pLKO.1 backbones were
obtained from the Mission TRC shRNA library (Sigma-Aldrich). Lentiviral
shRNAs were produced in HEK293T cells after co-transfection of shControl,
sh19, or sh20 together with the packaging plasmids pSPAX2 and pMDG.2.
HUVECs were infected with lentivirus for 24 hr and selected for 5 days with
2mg/mL of puromycin.
Statistics
Statistical analyses were performed using Prism 5 (GraphPad Software).
Unless otherwise specified, unpaired, 2-tailed Student’s t test (single test for
comparison of 2 means) or 1-way ANOVA followed by Bonferroni correction
for multiple comparisons were used to evaluate statistical significance,
defined as p < 0.05. All results in bar graphs are means ± SEMs.
DATA AND SOFTWARE AVAILABILITY
The accession number for the RNA-seq data derived from human healthy
adults, AML day 17 patients, and fetal bone specimens is European
Genome-phenome Archive: EGAS00001002736.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and one table and can be found with this article online at
https://doi.org/10.1016/j.celrep.2017.12.070.
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